This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01584-07v1 52/6/2276    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Urich, S. K. Articles by Petersen, J. M. PubMed PubMed Citation Articles by Urich, S. K. Articles by Petersen, J. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 2276-2278, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.01584-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Susceptibility of Isolates of Francisella tularensis Types A and B from North America

Bacterial Diseases Branch, Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado

Received 7 December 2007/ Returned for modification 9 March 2008/ Accepted 5 April 2008

Due to concern that Francisella tularensis, the causative agent of tularemia, may be used as a bioterrorist weapon, the Clinical and Laboratory Standards Institute recently provided a susceptibility testing method with breakpoints. Here, 169 isolates (92 type A and 77 type B) from North America were tested against seven antimicrobial agents (streptomycin, gentamicin, tetracycline, doxycycline, ciprofloxacin, levofloxacin, and chloramphenicol) used for the treatment of tularemia. The MICs for all of the isolates fell within the susceptible range. In addition, all isolates had MICs for erythromycin of 0.5 to 4 µg/ml, in contrast to an MIC of >256 µg/ml for the common laboratory strain LVS (live vaccine strain).

Published ahead of print on 14 April 2008.